Program Information


CME Breakfast Symposium
7:00 AM – 11:00 AM

Hyatt Regency Orlando
Regency Ballroom R
9801 International Drive
Orlando, FL 32819


7:00 AM
Registration and Breakfast
7:40 AM
LLS Overview
Lee Greenberger, PhD
Chief Scientific Officer, The Leukemia & Lymphoma Society (LLS)
7:45 AM
Cheryl L. Willman, MD (Chair)
7:50 AM
Advances in Pediatric Therapy
Stephen P. Hunger, MD
8:20 AM
Improving Myeloma Outcomes
C. Ola Landgren, MD, PhD
8:50 AM
Lymphoma: Entering a New Era
Philippe Armand, MD, PhD
9:20 AM
Translational Landscape of Cell Therapy for AML: CARs and Beyond
Catherine Bollard, MD, FRACP, FRCPA
9:50 AM
Prevention is the Best Medicine
Benjamin L. Ebert, MD, PhD
10:20 AM
Panel Discussion and Q&A
All Faculty
11:00 AM


Cheryl L. Willman, MD (Chair)
The Maurice and Marguerite Liberman Distinguished Endowed Chair in Cancer Research
UNM Distinguished Professor of Pathology, UNM School of Medicine
Director & CEO, University of New Mexico Comprehensive Cancer Center
Albuquerque, NM
Philippe Armand, MD, PhD
Harold and Virginia Lash/David Lash Chair in Lymphoma Research
Chief, Lymphoma Division
Dana-Farber Cancer Institute
Boston, MA
Catherine Bollard, MD, FRACP, FRCPA
Bosworth Chair for Cancer Biology
Professor of Pediatrics and Microbiology, Immunology and Tropical Medicine
Director, Center for Cancer and Immunology Research
Director, Program for Cell Enhancement and Technologies for Immunotherapy
Children’s National Health System
The George Washington University, School of Medicine and Health Sciences
Washington, DC
Benjamin L. Ebert, MD, PhD
George P. Canellos, MD and Jean S. Canellos Professor of Medicine
Harvard Medical School
Chair, Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Investigator, Howard Hughes Medical Institute
Stephen P. Hunger, MD
Chief, Division of Oncology
Director, Center for Childhood Cancer Research
Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics
Children’s Hospital of Philadelphia
Professor, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA
C. Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

After completing this activity, participants should be better able to:

  • Describe the latest advances in translational medicine for patients with acute myeloid leukemia (AML), multiple myeloma, lymphoma, and pediatric leukemia
  • Explain how novel genetic screening strategies currently in development may be used to identify patients at risk of developing hematologic malignancies and direct early intervention strategies
  • Select the most appropriate treatment among current and emerging options for patients with hematologic malignancies
  • Identify novel treatment strategies that may improve patient quality of life by reducing toxicity of treatment and prolonging disease control


Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, The Leukemia & Lymphoma Society, and RMEI Medical Education LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

There is no fee for this educational activity.


Event staff will be glad to assist you with any special needs (physical, dietary, etc.).
Please contact us prior to the live event at (866) 992-9950.

This activity is jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.

The educational portion of this program is supported by independent educational grants from Amgen, AstraZeneca Pharmaceuticals LP, and Celgene Corporation. Additional funding provided by The Leukemia & Lymphoma Society.

For information on leukemia, lymphoma, or myeloma, contact an LLS Information Specialist at (800) 955-4572 or, or visit

Facebook Twitter YouTube